RCS - Creo Medical Group - Investor Presentation

Creo MedicalAnnouncement

12/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231012:nRSL8280Pa&default-theme=true

RNS Number : 8280P  Creo Medical Group PLC  12 October 2023

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Investor Presentation

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that Creo will deliver a
presentation providing an overview of the Company at a hybrid event in London
hosted by the UK Individual Shareholders' Society (ShareSoc) on Thursday 19
October 2023 and available to ShareSoc members via the link below:

 

https://www.sharesoc.org/sharesoc-walbrook-pr-healthcare-companies-hybrid-event-london-19-october-2023-5pm/
(https://www.sharesoc.org/sharesoc-walbrook-pr-healthcare-companies-hybrid-event-london-19-october-2023-5pm/)

 

Craig Gulliford, Chief Executive Officer will deliver an "in-person"
presentation which will also be streamed live (and recorded), allowing
ShareSoc members to watch virtually. No new material information will be
disclosed in the presentation.

 

An online presentation covering the Company's interim results for the six
months ended 30 June 2023, and presented on 12 September 2023, is available
for all investors on the Investor Meet Company platform and can be accessed
via this link:
https://www.investormeetcompany.com/investor/meeting/investor-presentation-421
(https://www.investormeetcompany.com/investor/meeting/investor-presentation-421)

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cavendish Securities plc                           +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Numis Securities Limited (Joint Broker)            +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEALEFFFNDFFA